Cemiplimab trials for Lung cancer

All Cemiplimab trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Cemiplimab for Lung cancer

• A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
  NCT06931717 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
  NCT06908304 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
  NCT06090266 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
  NCT06616584 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 386 locations
• Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
  NCT06656598 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
  NCT05363319 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
  NCT05317858 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 14 locations
• Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
  NCT05142189 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
  NCT06731270 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
  NCT06532149 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: Male · 1 location
• Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
  NCT06088771 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
  NCT07001618 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• PALACE: Cemiplimab Trial According to ctDNA Levels
  NCT06917573 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
  NCT06171750 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
  NCT06623656 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
  NCT07020065 · Phase: Phase 2 · Ages: 70 Years and older · Sex: All (male and female) · 17 locations
• Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
  NCT05501665 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
  NCT06743581 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
  NCT06865339 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
  NCT07234058 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 37 locations

Common questions

How many trials study Cemiplimab for Lung cancer?

20 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.